<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">LEVOFLOXACIN</span><br/>(lev-o-flox'a-sin)<br/><span class="topboxtradename">Levaquin, </span><span class="topboxtradename">Iquix, </span><span class="topboxtradename">Quixin<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic</span>; <span class="classification">quinolone</span><br/><b>Prototype: </b>Ciprofloxacin<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>250 mg, 500 mg, 750 mg tablets; 25 mg/mL solution; 250 mg, 500 mg, 750 mg injection; 0.5% ophthalmic solution</p>
<h1><a name="action">Actions</a></h1>
<p>A broad-spectrum fluoroquinolone antibiotic that inhibits DNA-gyrase, an enzyme necessary for bacterial replication, transcription,
         repair, and recombination.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Effective against many gram-positive and gram-negative organisms.</p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of maxillary sinusitis, acute exacerbations of bacterial bronchitis, community-acquired pneumonia, uncomplicated
         skin/skin structure infections, UTI, acute pyelonephritis caused by susceptible bacteria; acute bacterial sinusitis; chronic
         bacterial prostatitis; bacterial conjunctivitis.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to levofloxacin and quinolone antibiotics; hypokalemia, tendon pain, pregnancy (category C); syphilis; viral
         infections; phototoxicity; lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Known or suspected CNS disorders predisposed to seizure activity (e.g., severe cerebral atherosclerosis), risk factors associated
         with potential seizures (e.g., some drug therapy, renal insufficiency), dehydration, colitis; QT prolongation, cardiac arrhythmias;
         renal impairment; diabetes; patients receiving theophylline or caffeine; older adults. Safety and efficacy in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 500 mg q24h <small>x</small> 10 d <span class="rdroute">IV</span> 500 mg infused over 60 min q24h <small>x</small> 714 d<br/><br/><span class="indicationtitle">Community-Acquired Pneumonia</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO/IV</span> 750 mg q24h <small>x</small> 5 d<br/><br/><span class="indicationtitle">Uncomplicated UTI</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 250 mg q24h <small>x</small> 14 d<br/><br/><span class="indicationtitle">Complicated UTI, Pyelonephritis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 250 mg q24h <small>x</small> 10 d <span class="rdroute">IV</span> 250 mg infused over 60 min q24h <small>x</small> 10 d<br/><br/><span class="indicationtitle">Acute Bacterial Sinusitis</span><br/><span class="rdroute"></span> 750 mg q.d. <small>x</small> 5 d<br/><br/><span class="indicationtitle">Chronic Bacterial Prostatitis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 500 mg q24h <small>x</small> 28 d<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Give an initial dose of 500 mg with adjusted maintenance doses as follows; Cl<sub>cr</sub> 2050 mg/min: 250 mg q24h; <br/><span class="indicationtitle">Skin &amp; Skin Structure Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 750 mg q24h <small>x</small> 14 d<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Give an initial dose of 250 mg with adjusted maintenance doses as follows; Cl<sub>cr</sub> <br/><span class="indicationtitle">Bacterial Conjunctivitis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">Ophthalmic</span> Days 12, 12 drops in affected eye(s) q2h while awake (max: 8 times/d), days 37, 12 drops in affected
               eye(s) q4h while awake (max: 4 times/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Do not give oral drug within 2 h of drugs containing aluminum or magnesium (antacids), iron, zinc, or sucralfate.</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Intermittent:</span> Withdraw the desired dose from 500 mg (25 mg/mL) single-use vial. Add to enough D5W, NS, D5/NS, D5/RL, or other compatible
                  solutions to produce a concentration of 5 mg/mL [e.g., 500 mg (or 20 mL) added to 80 mL]. Discard any unused drug remaining
                  in the vial.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype"> Intermittent:</span>  Give over <img src="../images/special/greaterorequal.gif"/>60 min. Do <small>NOT</small> give a bolus dose or infuse too rapidly.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Y-site:</span> Do not add any drugs to levofloxacin solution or infuse simultaneously through the same line (manufacturer recommendation).
                  <b>Amiodarone,</b>
<b>azithromycin.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Store tablets in a tightly closed container. IV solution is stable for 72 h at 25° C (77° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span> Headache, insomnia, dizziness. <span class="typehead">GI:</span> Nausea, diarrhea, constipation, vomiting, abdominal pain, dyspepsia. <span class="typehead">Skin:</span> Rash, pruritus. <span class="typehead">Special Senses:</span> Decreased vision, foreign body sensation, transient ocular burning, ocular pain, photophobia. <span class="typehead">Urogenital:</span> Vaginitis. <span class="typehead">Body as a Whole:</span> Injection site pain or inflammation, chest or back pain, fever, pharyngitis. <span class="typehead">Other:</span> Cartilage erosion. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>May cause false positive on <span class="alt">opiate screening tests.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Magnesium </b>or <b>aluminum</b>-containing antacids,<b></b>
<b>sucralfate,</b>
<b>iron,</b>
<b>zinc</b> may decrease levofloxacin absorption; <b></b>
<span class="classification">nsaid</span>s may increase risk of CNS reactions, including seizures; may cause hyper- or hypoglycemia in patients on <span class="classification">oral hypoglycemic agents</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Rapidly absorbed from GI tract. <span class="typehead">Peak:</span> PO 12 h. <span class="typehead">Distribution:</span> Penetrates lung tissue, 2438% protein bound. <span class="typehead">Metabolism:</span> Minimally metabolized in the liver. <span class="typehead">Elimination:</span> Primarily excreted unchanged in urine. <span class="typehead">Half-Life:</span> 68 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Do C&amp;S test prior to beginning therapy and periodically.</li>
<li>Withhold therapy and report to physician immediately any of the following: Skin rash or other signs of a hypersensitivity
            reaction (see Appendix F); CNS symptoms such as seizures, restlessness, confusion, hallucinations, depression; skin eruption
            following sun exposure; symptoms of colitis such as persistent diarrhea; joint pain, inflammation, or rupture of a tendon;
            hypoglycemic reaction in diabetic on an oral hypoglycemic agent.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Learn important indications for discontinuing drug and immediately notifying physician.</li>
<li>Consume fluids liberally while taking levofloxacin.</li>
<li>Allow a minimum of 2 h between drug dosage and taking any of the following: Aluminum or magnesium antacids, iron supplements,
            multivitamins with zinc, or sucralfate.
         </li>
<li>Avoid exposure to excess sunlight or artificial UV light.</li>
<li>Avoid <small>NSAID</small>s while taking levofloxacin, if possible.
         </li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>